General Information of Drug (ID: DMD20YH)

Drug Name
SAR-650984 Drug Info
Synonyms Anti-CD38 monoclonal antibody (leukemia), ImmunoGen/sanofi-aventis
Indication
Disease Entry ICD 11 Status REF
Haematological malignancy 2B33.Y Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMD20YH

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclic ADP-ribose hydrolase 1 (CD38) TTPURFN CD38_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Cyclic ADP-ribose hydrolase 1 (CD38) DTT CD38 6.658 6.115 5.04 6.932
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Haematological malignancy
ICD Disease Classification 2B33.Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cyclic ADP-ribose hydrolase 1 (CD38) DTT CD38 8.33E-02 0.22 0.69
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01084252) Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Sanofi-Aventis.